Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study

Frederick E. Dewey(Regeneron (United States)), Michael F. Murray(Geisinger Health System), John D. Overton(Regeneron (United States)), Lukas Habegger(Regeneron (United States)), Joseph B. Leader(Geisinger Health System), Samantha N. Fetterolf(Geisinger Health System), Colm O’Dushlaine(Regeneron (United States)), Cristopher V. Van Hout(Regeneron (United States)), Jeffrey Staples(Regeneron (United States)), Claudia Gonzaga‐Jauregui(Regeneron (United States)), Raghu Metpally(Geisinger Health System), Sarah A. Pendergrass(Geisinger Health System), Monica A. Giovanni(Geisinger Health System), H. Lester Kirchner(Geisinger Health System), Suganthi Balasubramanian(Regeneron (United States)), Noura S. Abul‐Husn(Regeneron (United States)), Dustin N. Hartzel(Geisinger Health System), Daniel R. Lavage(Geisinger Health System), Korey A. Kost(Geisinger Health System), Jonathan S. Packer(Regeneron (United States)), Alexander Lopez(Regeneron (United States)), John S. Penn(Regeneron (United States)), Semanti Mukherjee(Regeneron (United States)), Nehal Gosalia(Regeneron (United States)), Manoj Kanagaraj(Regeneron (United States)), Alexander Li(Regeneron (United States)), Lyndon J. Mitnaul(Regeneron (United States)), Lance J. Adams(Geisinger Health System), Thomas N. Person(Geisinger Health System), Kavita Praveen(Regeneron (United States)), Anthony Marcketta(Regeneron (United States)), Matthew S. Lebo, Christina Austin‐Tse, Heather Mason‐Suares, Shannon Bruse(Regeneron (United States)), Scott Mellis(Regeneron (United States)), Robert S. Phillips(Regeneron (United States)), Neil Stahl(Regeneron (United States)), Andrew Murphy(Regeneron (United States)), Aris N. Economides(Regeneron (United States)), Kimberly A. Skelding(Geisinger Health System), Christopher D. Still(Geisinger Health System), James R. Elmore(Geisinger Health System), Ingrid B. Borecki(Regeneron (United States)), George D. Yancopoulos(Regeneron (United States)), F. Daniel Davis(Geisinger Health System), W. Andrew Faucett(Geisinger Health System), Omri Gottesman(Regeneron (United States)), Marylyn D. Ritchie(Geisinger Health System), Alan R. Shuldiner(Regeneron (United States)), Jeffrey G. Reid(Regeneron (United States)), David H. Ledbetter(Geisinger Health System), Aris Baras(Regeneron (United States)), David J. Carey(Geisinger Health System)
Science
December 22, 2016
Cited by 599

Abstract

The DiscovEHR collaboration between the Regeneron Genetics Center and Geisinger Health System couples high-throughput sequencing to an integrated health care system using longitudinal electronic health records (EHRs). We sequenced the exomes of 50,726 adult participants in the DiscovEHR study to identify ~4.2 million rare single-nucleotide variants and insertion/deletion events, of which ~176,000 are predicted to result in a loss of gene function. Linking these data to EHR-derived clinical phenotypes, we find clinical associations supporting therapeutic targets, including genes encoding drug targets for lipid lowering, and identify previously unidentified rare alleles associated with lipid levels and other blood level traits. About 3.5% of individuals harbor deleterious variants in 76 clinically actionable genes. The DiscovEHR data set provides a blueprint for large-scale precision medicine initiatives and genomics-guided therapeutic discovery.


Related Papers

No related papers found

Powered by citation graph analysis